Compare Gilead Sciences, Inc. (GILD) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Oscar Health Inc — how do they compare? Gilead Sciences, Inc. trades at $133.71 (market cap $163.51B), while Oscar Health Inc trades at $29.89 (market cap $9.23B). The key difference: Gilead Sciences, Inc. is far larger — about 17.7× Oscar Health Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| GILD | OSCR | |
|---|---|---|
Market Cap | $163.51B | $9.23B |
Sector | Health | Health |
52-Week High | $155.80 | $32.18 |
52-Week Low | $108.22 | $10.85 |
Enterprise Value | $178.05B | $4.85B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Oscar Health (OSCR) trades at $30.73, down 1.09% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong revenue growth, with 2026 revenue projected at $13.3 billion, but remains unprofitable with a net margin of -0.3%. Recent news highlights its momentum, including a 102.8% year-to-date gain and positive coverage from The Motley Fool and Zacks.
The outlook is mixed: strong revenue growth and bullish technicals offer upside potential, but profitability challenges and a consensus price target below the current price signal caution. Key risks include execution in a competitive insurance market and sustained losses. Analyst sentiment is divided, with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
